Clinical Trials Browser

Interventional × Gefitinib × 1 year × Clear all

NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Phase 2 Recruiting

45 enrolled

Sarcoma

Neoplasm Metastasis, Osteosarcoma

NCT07458919 2026-03-09

Therapy for Advanced NSCLC With EGFR 19delins Mutation

Phase EARLY_PHASE1 Not yet recruiting

94 enrolled

Thoracic

Lung Neoplasms

NCT02411448 2026-01-16

RELAY

Phase 3 Active not recruiting

545 enrolled 24 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Phase 1 Active not recruiting

105 enrolled

Thoracic

EGFR-mutant Non-small Cell Lung Cancer

NCT02296125 2026-01-09

FLAURA

Phase 3 Completed

674 enrolled 21 charts 1 FDA

Thoracic

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Active not recruiting

30 enrolled

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03122717 2025-11-12

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Phase 1/2 Active not recruiting

48 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03653546 2025-09-10

BM

Phase 2/3 Completed

492 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT03292133 2025-06-10

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Phase 2 Terminated

11 enrolled 10 charts

Thoracic

Lung Neoplasms

NCT00328562 2025-05-04

ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer

Phase 1 Completed

13 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03787992 2025-04-11

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Phase 3 Active not recruiting

358 enrolled

Thoracic

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer